BPC-157: A Short-Lived Molecule With Long-Running Claims

The short version

BPC-157 stands for Body Protection Compound 157. It is a synthetic chain of 15 amino acids copied from part of a protein found in human gastric juice, and it is the most-studied compound on this desk.

Almost all of that study was done in rats. In animals, BPC-157 has been reported to speed the healing of a cut Achilles tendon ^[6] and to shrink stomach ulcers ^[5], and the mechanism most often credited for those results is angiogenesis — the growth of new blood vessels into damaged tissue ^[4].

The timing is the strange part. When researchers finally measured how long the molecule stays in the body, they found it disappears in under half an hour in rats and dogs ^[3], while the healing it is credited with takes days. Whatever it does appears to be a short signal with long consequences, and nobody has shown exactly how that works.

In people, the record is three small pilot studies ^[2]. That is the whole human timeline.

What it is

BPC-157 is a pentadecapeptide — a 15-amino-acid chain with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and the molecular formula C62H98N16O22. It derives from a partial sequence of Body Protection Compound, a protein identified in human gastric juice. It also circulates in the literature and in commerce under several other designations: Pentadecapeptide BPC 157, PL 14736, PLD-116, PL-10 and Bepecin.

It is classed as a stable gastric pentadecapeptide and, more usefully for a reader, as a cytoprotective and regenerative research peptide that is not an approved drug. The United States Food and Drug Administration has not approved it for human use; in 2023 it was placed in a category of bulk drug substances identified as not eligible for pharmacy compounding under section 503A, pending further evaluation. The World Anti-Doping Agency prohibits it in sport at all times under the S0 non-approved-substances category. Suppliers sell it for laboratory research use only, and it has no established human therapeutic indication.

Those three facts — unapproved, prohibited in tested sport, unregulated in distribution — frame every timeline below.

How it works

The repair effects attributed to BPC-157 in animal models are most consistently linked to angiogenesis. The best-characterised route is up-regulation and internalisation of the VEGFR2 receptor, with downstream signalling through the VEGFR2-Akt-eNOS pathway; work across chick chorioallantoic membrane, a rat hindlimb-ischaemia model and human vascular endothelial cells reported increased vessel density and accelerated recovery of blood flow in ischaemic muscle, with the effect blocked when endocytosis was inhibited ^[4].

Several additional routes are described in the literature: FAK-paxillin signalling associated with cell migration, sensitisation of the growth-hormone receptor in tendon fibroblasts, and modulation of the nitric-oxide system. A 2016 review positions the peptide as a brain-gut-axis mediator that modulates serotonergic and dopaminergic systems and engages the Egr-1, NAB2, FAK-paxillin and JAK-2 pathways ^[7].

Read as a clock, the mechanism story is coherent with the pharmacokinetics rather than contradicted by them. Angiogenesis and cell migration are processes the body sustains on its own once triggered; a signal that starts them does not have to persist while they run. That is a plausible reconciliation of a half-hour molecule with a multi-day outcome — but it is a reconciliation, not a finding. No study in this corpus tracked a repair process forward from a single administration to establish it.

What the research shows, and when it was measured

The findings below are arranged by what they say about time rather than by date of publication.

The molecule's own clock. The first formal pharmacokinetic, distribution, metabolism and excretion characterisation of BPC-157 was published in 2022 using rats and beagle dogs. It found linear pharmacokinetics, an elimination half-life under 30 minutes, intramuscular bioavailability of approximately 14 to 19 per cent in rats and 45 to 51 per cent in dogs, rapid breakdown into small peptide fragments entering normal amino-acid metabolism, and excretion via urine and bile ^[3]. This is the single most important number on the page, because every longer interval in the literature has to be explained across it.

Repair measured over days, in rodents. In Wistar rats with a fully transected Achilles tendon, BPC-157 accelerated healing across biomechanical, functional, microscopic and macroscopic measures, with better collagen organisation and restored tendon integrity relative to untreated controls, and stimulated tendocyte outgrowth in culture ^[6]. In a rat gastric-ulcer model, it reduced ulcer area and accelerated healing, with an ulcer-formation inhibition ratio of 45.7 to 65.6 per cent at higher doses and faster rebuilding of glandular epithelium and granulation tissue; intramuscular delivery outperformed intragastric ^[5]. Both are animal studies. Neither reports a human interval.

The human record, in full. A first-in-human intravenous safety pilot administered BPC-157 at up to 20 mg to two healthy adults, a 58-year-old man and a 68-year-old woman. It was well tolerated, with no observed adverse events and no measurable change in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[1]. The sample is two people and the study was not designed to measure efficacy. A 2025 narrative review of BPC-157 for musculoskeletal healing concluded that only three pilot studies have examined the compound in humans, that rigorous large-scale trials are lacking, and that it should be considered investigational and used with caution given the regulatory controversy and non-regulated availability ^[2]. A 2025 systematic review in orthopaedic sports medicine reached the same place from a different direction: 36 studies, of which 35 were preclinical and one was a 12-patient retrospective report, no clinical safety data found, and evidence graded at levels IV to V ^[13].

So the honest summary of the time axis is this. Duration of effect: measured in rats. Onset of effect: not systematically measured in any species. Persistence after stopping: not measured. Human healing interval: no data.

Reported effects, cautions and safety

The accounts in this section come from research-use forums, wellness-clinic write-ups and published discussions of online reports. They are anecdotal, not clinical evidence, they are not measurements, and no doses are attached to any of them.

What is striking about these accounts, for a desk organised around time, is how confidently they are dated — and how little supports the dates. Faster recovery from tendon, ligament and joint problems is very commonly reported, often described as arriving within the first one to three weeks; reduced joint stiffness and pain is frequently reported on a similar one-to-two-week framing; improved digestive symptoms are frequently reported, again usually in the first week or two, which people connect to the peptide's origin in gastric juice. Reported less often are a general sense of reduced inflammation, faster closure of minor skin wounds, and better sleep, mood or stress tolerance — the last of which commentators note could as easily follow from sleeping better with less pain as from any direct effect. On the adverse side, injection-site redness, stinging or a small bump is very commonly reported and usually described as fading within a day; mild nausea or loose stools are frequently reported in the first few days; and fatigue during the first week, headache, brief dizziness after a dose and transient flushing are each occasionally reported. Palpitations are rarely reported, and commentators treat persistent rapid heartbeat, chest pain or marked blood-pressure change as reasons to stop and seek medical evaluation. None of these intervals has been measured under study conditions.

The documented cautions are these. The human evidence base is extremely thin: essentially everything known comes from rodent studies, only a handful of small uncontrolled human pilot reports exist, and large rigorous controlled trials are absent, so the real balance of benefit and risk in people is unknown ^[1][2]. Much of the foundational literature comes from a single research group and its collaborators, which newer reviewers explicitly flag as an independent-replication problem ^[2]. The compound is not an approved medicine anywhere and moves through non-regulated channels, so the identity, purity and actual content of any given product are unverified outside formal studies ^[2]. Its strong pro-angiogenic activity raises a theoretical concern in cancer, because tumours also depend on new blood-vessel growth — this is mechanism-based reasoning from the VEGFR2 work rather than a human finding ^[4]. Rodent evidence that the peptide alters brain serotonin activity underlies a theoretical concern about combining it with serotonin-raising medicines; no human interaction study exists ^[7]. Because it increases growth-hormone-receptor signalling in cultured tendon cells, any long-term effect on tissue growth is an open question with no long-term human safety data to settle it. It is prohibited at all times in sport. And it has never been studied in pregnancy, breastfeeding or children.

Where it sits on the repair timeline

BPC-157 is the lead compound here because it has the densest evidence base and the sharpest time problem.

On the phase question, the literature points early rather than late. Angiogenesis and granulation-tissue formation are proliferative-phase activities, and those are exactly the endpoints the rodent work reports ^[4][5]. There is no study in this corpus that follows a repaired tissue through remodelling to ask whether an early acceleration produces a better final structure, or only an earlier-looking one.

On the duration question, the record is close to silent. A sub-thirty-minute half-life ^[3] paired with multi-day outcomes ^[6] means the interesting interval — how long a single administration keeps influencing repair — has never been characterised in any species.

And on the human question, the timeline consists of three pilot studies ^[2], one of which enrolled two people ^[1]. Against a compound whose community reputation is built on three-week recovery stories, that is the entire measured record. The comparison page sets this against the other two members, and the reference list gives every source in full.